Remdesivir in covid-19

Ferner, Robin E; Aronson, Jeffrey K

doi:10.1136/bmj.m1610

Cited by 103 publications

(79 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…can be used as positive controls. In the case of the antiviral drugs, we recommend to use remdesivir since it has been shown to have antiviral activity against SARS-CoV-2 (Choy et al, 2020;Ferner and Aronson, 2020). Negative controls include the use of SARS-CoV-2-infected Vero E6 cells without NAbs, sera, or drugs.…”

Section: Drugsmentioning

confidence: 99%

Rapidin vitroassays for screening neutralizing antibodies and antivirals against SARS-CoV-2

Park

Oladduni

Chiem

et al. 2020

Preprint

View full text Add to dashboard Cite

Towards the end of 2019, a novel coronavirus (CoV) named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), genetically similar to severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1), emerged in Wuhan, Hubei province of China, and has been responsible of coronavirus disease 2019 (COVID-19) in humans. Since its first report, SARS-CoV-2 has resulted in a global pandemic, with over 10 million human infections and over 560,000 deaths reported worldwide at the end of June 2020. Currently, there are no United States (US) Food and Drug Administration (FDA)-approved vaccines and/or antivirals licensed against SARS-CoV-2, and the high economical and health impact of SARS-CoV-2 has placed global pressure on the scientific community to identify effective prophylactic and therapeutic treatments for the treatment of SARS-CoV-2 infection and associated COVID-19 disease. While some compounds have been already reported to reduce SARS-CoV-2 infection and a handful of monoclonal antibodies (mAbs) have been described that neutralize SARS-CoV-2, there is an urgent need for the development and standardization of assays which can be used in high through-put screening (HTS) settings to identify new antivirals and/or neutralizing mAbs against SARS-CoV-2. Here, we described a rapid, accurate and highly reproducible plaque reduction microneutralization (PRMNT) assay that can be quickly adapted for the identification and characterization of both neutralizing mAbs and antivirals against SARS-CoV-2. Importantly, our MNA is compatible with HTS settings to interrogate large and/or complex libraries of mAbs and/or antivirals to identify those with neutralizing and/or antiviral activity, respectively, against SARS-CoV-2.

show abstract

Section: Drugsmentioning

confidence: 99%

Rapidin vitroassays for screening neutralizing antibodies and antivirals against SARS-CoV-2

Park

Oladduni

Chiem

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…It will test their ability to develop new strategies and adequate pharmaceutical policies and regulations in order to respond to the challenges that the Bulgarian health care system currently faces. 11,20 We suggest that the regulation update in the era of CO-VID-19 will potentially initiate a dialogue among stakeholders for reforms in the legal framework regarding CU, not only in Bulgaria but also in other EU Member States in order to correspond to higher demand of patients for investigational drugs and new promising therapies.…”

Section: Discussionmentioning

confidence: 99%

“…Remdesivir is an active adenosine analogue that enters and accumulates in cells, inhibiting viral RdRp4 and stopping viral replication. 11 Coronaviruses (e.g., SARS/ MERS-CoV5, SARS-CoV-2) have a "proofreading" enzyme (exoribonuclease) that corrects errors in the RNA sequence, potentially limiting the effects of analogues 12,13 , but remdesivir is able to evade this proofreading. 14,15 In the laboratory, viral mutation can lead to resistance to remdesivir, but the mutantviruses are less infective.…”

Section: Methodsmentioning

confidence: 99%

Compassionate Drug Use – Time Arising for a New Law in Bulgaria in the Era of COVID-19

Dzhafer¹,

Papathanasiou²

2020

View full text Add to dashboard Cite

Nowadays the health care systems over the world are in a critical period trying to take control over the pandemic of COVID-19. The Bulgarian the Government introduced rapidly (8-to March 2020), restrictive control measures including general lockdown and social distancing. Despite several clinical trials, there are still no specific therapies or any vaccine against COVID-19. The only option available is using investigational drugs for compassionate use (CU). The global pandemic mandates Bulgarian Drug Agency (BDA) for a reasonable update of the existing national regulation concerning CU and off-label therapies. The update of the existing national regulation regarding CU is vital to ensure the effective and sustainable development of health policies and technologies over the COVID-19 pandemic and beyond.

show abstract

“…Therefore, remdesivir is described as a direct antiviral agent acting as a delayed chain terminator [ 30 , 31 ]. Importantly, remdesivir avoids proofreading by viral exoribonuclease [ 28 , 32 ]. Currently, remdesivir is being evaluated as a treatment for COVID-19 patients in about 15 studies across the globe.…”

Section: Viral Polymerase Inhibitorsmentioning

confidence: 99%

Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review

Al‐Horani

Kar

2020

Viruses

View full text Add to dashboard Cite

The coronavirus disease-2019 (COVID-19) pandemic continues to challenge health care systems around the world. Scientists and pharmaceutical companies have promptly responded by advancing potential therapeutics into clinical trials at an exponential rate. Initial encouraging results have been realized using remdesivir and dexamethasone. Yet, the research continues so as to identify better clinically relevant therapeutics that act either as prophylactics to prevent the infection or as treatments to limit the severity of COVID-19 and substantially decrease the mortality rate. Previously, we reviewed the potential therapeutics in clinical trials that block the early stage of the viral life cycle. In this review, we summarize potential anti-COVID-19 therapeutics that block/inhibit the post-entry stages of the viral life cycle. The review presents not only the chemical structures and mechanisms of the potential therapeutics under clinical investigation, i.e., listed in clinicaltrials.gov, but it also describes the relevant results of clinical trials. Their anti-inflammatory/immune-modulatory effects are also described. The reviewed therapeutics include small molecules, polypeptides, and monoclonal antibodies. At the molecular level, the therapeutics target viral proteins or processes that facilitate the post-entry stages of the viral infection. Frequent targets are the viral RNA-dependent RNA polymerase (RdRp) and the viral proteases such as papain-like protease (PLpro) and main protease (Mpro). Overall, we aim at presenting up-to-date details of anti-COVID-19 therapeutics so as to catalyze their potential effective use in fighting the pandemic.

show abstract

Remdesivir in covid-19

Abstract: A drug with potential—don’t waste time on uncontrolled observations

Cited by 103 publications

References 15 publications

Rapidin vitroassays for screening neutralizing antibodies and antivirals against SARS-CoV-2

Rapidin vitroassays for screening neutralizing antibodies and antivirals against SARS-CoV-2

Compassionate Drug Use – Time Arising for a New Law in Bulgaria in the Era of COVID-19

Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review

Contact Info

Product

Resources

About

Remdesivir in covid-19

Abstract: A drug with potential—don’t waste time on uncontrolled observations

Cited by 103 publications

References 15 publications

Rapidin vitroassays for screening neutralizing antibodies and antivirals against SARS-CoV-2

Rapidin vitroassays for screening neutralizing antibodies and antivirals against SARS-CoV-2

Compassionate Drug Use &ndash; Time Arising for a New Law in Bulgaria in the Era of COVID-19

Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review

Contact Info

Product

Resources

About

Compassionate Drug Use – Time Arising for a New Law in Bulgaria in the Era of COVID-19